SCHEMBL5886740

SCHEMBL5886740

CCOC(=O)c1ccc(NC(=O)c2ccc(-n3c(=O)ccc4c(C)nc(N5CCc6ccccc6C5)nc43)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOD1 Q9Y239 5/20 0.53
RAB9A P51151 5/20 0.53
TNF P01375 4/20 0.53
NPC1 O15118 4/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
NOD2 Q9HC29 3/20 0.53
MAPT P10636 3/20 0.48
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48
TSHR P16473 2/20 0.48
MAPK1 P28482 1/20 0.48
HSD17B10 Q99714 1/20 0.48
POLB P06746 2/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
GAA P10253 1/20 0.44
TP53 P04637 1/20 0.43
LMNA P02545 1/20 0.41
GRIN2D O15399 2/20 0.40
GRIN3B O60391 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886828 0.86 NAMPT (0.49) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL5886800 0.85 NOD1 (0.50) NOD1RAB9ATNFNPC1MEN1
SCHEMBL5887343 0.83 PRMT5 (0.43) RAB9AMEN1KMT2AMAPTKDM4E
SCHEMBL5886729 0.82 ALDH1A1 (0.37) KDM4EALDH1A1
SCHEMBL5886784 0.82 NAMPT (0.47) MAPTTP53
SCHEMBL5886750 0.82 ADAMTS4 (0.45) MAPTALDH1A1POLBSMN1; SMN2TP53
SCHEMBL5886722 0.82 RXRA (0.46) MAPTKDM4EALDH1A1MAPK1
SCHEMBL5887057 0.82 DRD2 (0.41) RAB9ANPC1MAPTTSHRSMN1; SMN2
SCHEMBL5887054 0.81 HDAC6 (0.46) MAPTALDH1A1GAATP53LMNA
SCHEMBL5887072 0.81 ALDH1A1 (0.40) RAB9ANPC1MAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US disclosed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP NOD1 2342/4885RAB9A 3217/4885TNF 4097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.